0I1B Stock Chart & Stats
$29.16
$0.93(3.19%)
At close: 4:00 PM EDT
$29.16
$0.93(3.19%)
Day’s Range― - ―
52-Week Range$19.20 - $33.45
Previous CloseN/A
Volume31.00
Average Volume (3M)518.00
Market Cap
$1.50B
Enterprise Value$2.65K
Total Cash (Recent Filing)$12.56M
Total Debt (Recent Filing)$1.37B
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 11, 2026EPS Estimate
0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.40
Shares Outstanding57,669,495
10 Day Avg. Volume339
30 Day Avg. Volume518
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.02
Price to Sales (P/S)0.67
P/FCF Ratio75.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$39.56Price Target Upside35.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)3.63
Revenue Forecast (FY)$2.34B
Bulls Say, Bears Say
Bulls Say
Cash Generation And Improving Free Cash FlowSustained positive operating cash flow and emerging free cash flow provide durable internal funding for R&D, capex for instrumentation, and debt service. Management’s >25% free cash flow conversion target anchors capital allocation discipline and lowers reliance on external financing over the medium term.
High And Improving Gross MarginsConsistently strong gross margins reflect favorable product mix, productivity gains, and pricing power in Recon and instrumentation. Margin expansion supports sustainable EBITDA generation, funds reinvestment in innovation, and helps absorb structural cost headwinds like tariffs without immediate margin erosion.
Recon Segment Momentum And Innovation-led Share GainsDurable commercial traction in Recon, supported by new systems (Nebula, Arvis) and growing ASC adoption, evidences product-led share gains and higher-margin instrumentation sales. This structural shift toward procedure conversions and ASC channels should sustain revenue quality and long-term addressable market expansion.
Bears Say
Very Large Net Losses And Negative ROEDeep cumulative losses and sharply negative ROE indicate the company has yet to demonstrate consistent earnings power. Persistent losses can limit reinvestment flexibility, elevate the cost of capital, and constrain strategic optionality unless sustained cash generation fully bridges the profitability gap over coming quarters.
Notable Leverage With Debt Near EquityDebt roughly equal to equity raises financial risk and interest burden, reducing balance-sheet flexibility for M&A or cyclical downturns. Even with improving cash flow, this leverage level increases sensitivity to cash-flow volatility and may constrain capital allocation until deleveraging or sustained net profitability occurs.
Reporting Comparability, Tariffs And Geopolitical ExposureAn SEC-driven change to adjusted EBITDA reduces non-GAAP comparability versus prior periods, complicating trend analysis of underlying performance. Concurrent, recurring tariff costs and regional revenue exposure represent structural margin headwinds that may require pricing or mix shifts to fully mitigate.
Enovis News
0I1B FAQ
What was Enovis’s price range in the past 12 months?
Enovis lowest share price was $19.20 and its highest was $33.45 in the past 12 months.
What is Enovis’s market cap?
Enovis’s market cap is $1.50B.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Nov 11, 2026 which is in 85 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on Aug 06, 2026. The company reported $0.9 earnings per share for the quarter, beating the consensus estimate of $0.847 by $0.053.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis does not currently pay dividends.
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.77.
How many shares outstanding does Enovis have?
Enovis has 57,669,495 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of $0.9 in its last earnings report, beating expectations of $0.847. Following the earnings report the stock price went down -12.475%.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in GB:0I1B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.56 (35.65% Upside)
$39.56 (35.65% Upside)
Blogger Sentiment
Bullish
GB:0I1B Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $92.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.00%
Trailing 12-Months
Company Description
Enovis
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
0I1B Company Deck
0I1B Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed solid operational execution and clear commercial momentum—particularly in Recon and extremities—with meaningful innovation catalysts (Arvis, Nebula), margin expansion at the gross level, EPS growth, and improved free cash flow. However, offsetting risks include tariff costs (~$4M), international volatility including Middle East exposure (~$1–2M/month), a Q1 selling-days headwind (~240 bps), a conservative stance on guidance, and an SEC-driven change to adjusted EBITDA presentation that reduces non-GAAP comparability. On balance, positive fundamental performance and a constructive outlook outweigh the near-term headwinds and reporting adjustments.View all GB:0I1B earnings summaries0I1B Stock 12 Month Forecast
Average Price Target
$39.56
▲(35.65% Upside)